RCG
PVLA

Rock Creek Group’s Palvella Therapeutics PVLA Stock Holding History

Rock Creek Group’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-734
Closed -$122K – 208
2020
Q3 		$122K Sell
734
-75
-9% -$17.1K 0.06% 154
2020
Q2 		$201K Sell
809
-254
-24% -$59.4K 0.11% 135
2020
Q1 		$194K Buy
1,063
+63
+6% +$15.9K 0.11% 92
2019
Q4 		$290K Buy
1,000
+250
+33% +$69.3K 0.12% 105
2019
Q3 		$205K Sell
750
-188
-20% -$72.8K 0.1% 100
2019
Q2 		$353K Buy
+938
New +$280K 0.16% 95

Other funds holding PVLA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Rock Creek Group's PVLA Position: Q4 2020 in Review

Rock Creek Group sold out of Palvella Therapeutics (PVLA) in Q4 2020, closing a stake of 734 shares — an estimated $122K sold.

Rock Creek Group first reported a position in PVLA in Q2 2019 and held it in 6 quarters. The position peaked at $353K in Q2 2019. 82 funds tracked by Wall St. Rank hold PVLA as of Q4 2020.

  • Rock Creek Group reported no remaining Palvella Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Rock Creek Group sold 734 Palvella Therapeutics shares in Q4 2020, an estimated $122K.
  • Rock Creek Group first reported a position in Palvella Therapeutics in Q2 2019 and held it in 6 quarters.
  • Rock Creek Group's Palvella Therapeutics position peaked at $353K in Q2 2019.
  • 82 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q4 2020.

Based on Rock Creek Group's 13F filing for Q4 2020, filed 12 Feb 2021.